An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers (NCT07426757)
AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-07994525 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Who can join: Review the eligibility criteria below.
Location: Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables, Florida
- Sylvester Comprehensive Cancer Center - Coral Springs — Coral Springs, Florida
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida
- University of Miami Hospital and Clinics - Doral — Doral, Florida
- Sylvester Comprehensive Cancer Center - Hollywood — Hollywood, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- Sylvester Comprehensive Cancer Center- Kendall — Miami, Florida
- Sylvester Comprehensive Cancer Center - Sole Mia — North Miami, Florida
- Sylvester Comprehensive Cancer Center - Plantation — Plantation, Florida
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- Tristar BMT — Nashville, Tennessee
- TriStar Centennial Medical center — Nashville, Tennessee
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
- University Health Network- Princess Margaret Cancer Centre — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Malignancies
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing — Fayetteville, Arkansas
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) — Duarte, California
- Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies — New York, New York
Explore by condition: All Advanced Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.